Literature DB >> 23651555

Individuals' half-lives for 2,3,4,7,8-penta-chlorodibenzofuran (PeCDF) in blood: correlation with clinical manifestations and laboratory results in subjects with Yusho.

Shinya Matsumoto1, Manabu Akahane, Yoshiyuki Kanagawa, Jumboku Kajiwara, Takashi Todaka, Fumiko Yasukawa, Hiroshi Uchi, Masutaka Furue, Tomoaki Imamura.   

Abstract

BACKGROUND: In 1968, many people developed dioxin poisoning (Yusho) in Japan. Ingestion of 2,3,4,7,8-pentachlorodibenzofuran (2,3,4,7,8-PeCDF) was considered to be the cause of this poisoning. Although some patients had high concentrations of 2,3,4,7,8-PeCDF in their blood, individuals' half-lives of 2,3,4,7,8-PeCDF were long.
OBJECTIVES: To evaluate the relationship between clinical and laboratory parameters and the individual half-life of 2,3,4,7,8-PeCDF in blood.
METHODS: Clinical and laboratory data were collected during annual check-ups from 2001 to 2008. We enrolled 71 patients, who were measured more than 3 times, and who had 2,3,4,7,8-PeCDF concentrations in blood >50pgg(-1) lipid. The half-life of 2,3,4,7,8-PeCDF for each patient was estimated using linear regression. Moreover, relationships between clinical and laboratory parameters and individual half-life were investigated by linear regression.
RESULTS: A shortened individual half-life for 2,3,4,7,8-PeCDF was significantly correlated with an increased red blood cell count, increased viscous secretions from the meibomian glands, existing black comedones, and severe cedar pollen allergy.
CONCLUSIONS: Symptoms that accelerate excretion of lipids from the body, such as viscous secretions from the meibomian glands, may lead to a shorter half-life of 2,3,4,7,8-PeCDF. Red blood cells are related to the half-life of 2,3,4,7,8-PeCDF. However, further studies are required to investigate the excretory mechanism of 2,3,4,7,8-PeCDF.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651555     DOI: 10.1016/j.chemosphere.2013.04.005

Source DB:  PubMed          Journal:  Chemosphere        ISSN: 0045-6535            Impact factor:   7.086


  6 in total

1.  Current state of yusho and prospects for therapeutic strategies.

Authors:  Chikage Mitoma; Hiroshi Uchi; Kiyomi Tsukimori; Takashi Todaka; Jumboku Kajiwara; Takayuki Shimose; Manabu Akahane; Tomoaki Imamura; Masutaka Furue
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-01       Impact factor: 4.223

2.  Awareness and performance of blood transfusion standards in operating rooms of Shiraz hospitals in 2012.

Authors:  R Robati; E Mirahmadi Nejad
Journal:  Iran J Ped Hematol Oncol       Date:  2015-04-20

Review 3.  Aryl Hydrocarbon Receptor and Dioxin-Related Health Hazards-Lessons from Yusho.

Authors:  Masutaka Furue; Yuji Ishii; Kiyomi Tsukimori; Gaku Tsuji
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

4.  Unexpectedly long half-lives of blood 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) levels in Yusho patients.

Authors:  Shinya Matsumoto; Manabu Akahane; Yoshiyuki Kanagawa; Jumboku Kajiwara; Chikage Mitoma; Hiroshi Uchi; Masutaka Furue; Tomoaki Imamura
Journal:  Environ Health       Date:  2015-09-17       Impact factor: 5.984

Review 5.  Role of AhR/ARNT system in skin homeostasis.

Authors:  Masutaka Furue; Masakazu Takahara; Takeshi Nakahara; Hiroshi Uchi
Journal:  Arch Dermatol Res       Date:  2014-06-26       Impact factor: 3.017

Review 6.  Therapeutic Agents with AHR Inhibiting and NRF2 Activating Activity for Managing Chloracne.

Authors:  Masutaka Furue; Yoko Fuyuno; Chikage Mitoma; Hiroshi Uchi; Gaku Tsuji
Journal:  Antioxidants (Basel)       Date:  2018-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.